CRISPR Therapeutics AG

CRSPintermediary

CRISPR Therapeutics made history with the first FDA-approved CRISPR gene-editing therapy, Casgevy, for sickle cell disease. Co-founded by Nobel laureate Emmanuelle Charpentier, the company is leveraging its gene-editing platform across hematology, oncology (allogeneic CAR-T), and in vivo applications to create potentially curative one-time treatments.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($0.4B)

Data statis (memuat keuangan langsung…)

Casgevy Product Revenue (50%)

Collaboration Revenue (Vertex) (35%)

Grants & Other (15%)

Komposisi segmen dan pelanggan utama

Detail produk

Casgevy (Exagamglogene)50%

First CRISPR-based gene therapy approved for sickle cell disease and beta-thalassemia

CTX110 / Allogeneic CAR-T25%

Off-the-shelf CRISPR-edited CAR-T cell therapies for blood cancers

In Vivo Gene Editing25%

Next-gen lipid nanoparticle-delivered CRISPR for liver and other organs

Hubungan Rantai Pasok

Pesaing

Regeneron Pharmaceuticals

Gene editing and genomic medicine

Dampak: Competing modalities

Moderna, Inc.

Gene therapy delivery platforms

Dampak: Competing therapeutic platforms

Mitra

Alnylam Pharmaceuticals, Inc.

Complementary genetic medicine approaches

Dampak: Potential future collaboration

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok CRISPR Therapeutics AG.

Info Perusahaan

Kantor Pusat

Zug, Switzerland

Didirikan

2013

Karyawan

1,400+

Situs Web

crisprtx.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor